Pharmacokinetics and pharmacodynamics of dermorphin in the horse.

Robinson MA, Guan F, McDonnell S, Uboh CE, Soma LR

Journal of veterinary pharmacology and therapeutics5 Nov 2014Cited by 10 (Europe PMC)

PMID25376170DOI10.1111/jvp.12179PepBankPUB-25376170

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In horses, dermorphin bioavailability after intramuscular administration ranged from 47-100%.
In plain wordsIn horses, dermorphin bioavailability after muscle injection ranged from 47-100%.
Peptide
Dermorphin
Outcome
Not applicableIntramuscular bioavailability
Study
horsen = 3
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intramuscularAs given in this study (horse).
Measurements
Bioavailability
47 to 100%
intramuscular dermorphin
Source sentences
Summary
Bioavailability following intramuscular administration was variable (47-100%, n = 3).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617004
02AnimalAnimal study (in vivo)Pharmacokinetics
In horses, intravenous dermorphin had a distribution half-life of 0.09 ± 0.02 h.
In plain wordsIn horses, intravenous dermorphin had a distribution half-life of 0.09 ± 0.02 h.
Peptide
Dermorphin
Outcome
Not applicableIntravenous distribution half-life
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intravenousAs given in this study (horse).
Measurements
Distribution half-life
0.09 h
intravenous dermorphin
Source sentences
Summary
Data from intravenous administrations fit a 2-compartment model best with distribution and elimination half-lives (harmonic mean ± pseudo SD) of 0.09 ± 0.02 and 0.76 ± 0.22 h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617001
03AnimalAnimal study (in vivo)Pharmacokinetics
In horses, intravenous dermorphin had an elimination half-life of 0.76 ± 0.22 h.
In plain wordsIn horses, intravenous dermorphin had an elimination half-life of 0.76 ± 0.22 h.
Peptide
Dermorphin
Outcome
Not applicableIntravenous elimination half-life
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intravenousAs given in this study (horse).
Measurements
Elimination half-life
0.76 h
intravenous dermorphin
Source sentences
Summary
Data from intravenous administrations fit a 2-compartment model best with distribution and elimination half-lives (harmonic mean ± pseudo SD) of 0.09 ± 0.02 and 0.76 ± 0.22 h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617002
04AnimalAnimal study (in vivo)Pharmacokinetics
In horses, intramuscular dermorphin had a terminal elimination half-life of 0.68 ± 0.24 h.
In plain wordsIn horses, intramuscular dermorphin had a terminal elimination half-life of 0.68 ± 0.24 h.
Peptide
Dermorphin
Outcome
Not applicableIntramuscular terminal elimination half-life
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intramuscularAs given in this study (horse).
Measurements
Terminal elimination half-life
0.68 h
intramuscular dermorphin
Source sentences
Summary
Data from intramuscular administrations fit a noncompartmental model best with a terminal elimination half-life of 0.68 ± 0.24 (h).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617003
05AnimalAnimal study (in vivo)Pharmacokinetics
In horses, urinary dermorphin excretion was 5.0 (3.7-10.6) %.
In plain wordsIn horses, urinary dermorphin excretion was 5.0 (3.7-10.6) %.
Peptide
Dermorphin
Outcome
Not applicableUrinary excretion
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kgAs given in this study (horse).
Measurements
Urinary excretion
5%
dermorphin
Source sentences
Summary
The percentage of dermorphin excreted in urine was 5.0 (3.7-10.6) %.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617005
06AnimalAnimal study (in vivo)Safety outcome
In horses, excitation occurred only after intravenous dermorphin and subsided after 5 min.
In plain wordsIn horses, excitation occurred only after intravenous dermorphin and subsided after 5 min.
Peptide
Dermorphin
Outcome
IncreaseExcitation
Study
horsen: not reported in source
Horses
Outcome group
Adverse events · Nervous system and cognition
Studied dose
9.3 ± 1.0 μg/kg · intravenousAs given in this study (horse).
Source sentences
Summary
Excitation accompanied by an increased heart rate followed intravenous administration only and subsided after 5 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617006
07AnimalAnimal study (in vivo)Safety outcome
In horses, increased heart rate accompanied excitation only after intravenous dermorphin and subsided after 5 min.
In plain wordsIn horses, heart rate increased with excitation only after intravenous dermorphin, then recovered after 5 min.
Peptide
Dermorphin
Outcome
IncreaseHeart rate increase
Study
horsen: not reported in source
Horses
Outcome group
Heart function · Cardiovascular
Studied dose
9.3 ± 1.0 μg/kg · intravenousAs given in this study (horse).
Source sentences
Summary
Excitation accompanied by an increased heart rate followed intravenous administration only and subsided after 5 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617007
08AnimalAnimal study (in vivo)Activity measurement
In horses, the dermorphin concentration-response model for heart rate yielded an EC(50) of 21.1 ± 8.8 ng/mL.
In plain wordsIn horses, dermorphin's modeled half-maximal heart rate effect occurred at 21.1 ± 8.8 ng/mL.
Peptide
Dermorphin
Outcome
Not applicableHeart rate concentration-response EC50
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kgAs given in this study (horse).
Measurements
EC50
21.1 ng/mL
heart rate response
Source sentences
Summary
A plot of the mean change in heart rate vs. the plasma concentration of dermorphin fit a hyperbolic equation (simple Emax model), and an EC(50) of 21.1 ± 8.8 ng/mL was calculated.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617008
09AnimalAnimal study (in vivo)Pharmacokinetics
In horses, dermorphin remained detectable in plasma for 12 h after intravenous or intramuscular administration.
In plain wordsIn horses, dermorphin remained detectable in blood plasma for 12 h after intravenous or muscle injection.
Peptide
Dermorphin
Outcome
Not applicablePlasma detection duration
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kgAs given in this study (horse).
Measurements
Plasma detection duration
12 h
intravenous or intramuscular
Source sentences
Summary
Dermorphin was detected in plasma for 12 h and in urine for 48 or 72 h following intravenous or intramuscular administration, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617009
10AnimalAnimal study (in vivo)Pharmacokinetics
In horses, dermorphin remained detectable in urine for 48 h after intravenous administration.
In plain wordsIn horses, dermorphin remained detectable in urine for 48 h after intravenous injection.
Peptide
Dermorphin
Outcome
Not applicableUrine detection duration after intravenous administration
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intravenousAs given in this study (horse).
Measurements
Urine detection duration
48 h
intravenous
Source sentences
Summary
Dermorphin was detected in plasma for 12 h and in urine for 48 or 72 h following intravenous or intramuscular administration, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617010
11AnimalAnimal study (in vivo)Pharmacokinetics
In horses, dermorphin remained detectable in urine for 72 h after intramuscular administration.
In plain wordsIn horses, dermorphin remained detectable in urine for 72 h after muscle injection.
Peptide
Dermorphin
Outcome
Not applicableUrine detection duration after intramuscular administration
Study
horsen: not reported in source
Horses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
9.3 ± 1.0 μg/kg · intramuscularAs given in this study (horse).
Measurements
Urine detection duration
72 h
intramuscular
Source sentences
Summary
Dermorphin was detected in plasma for 12 h and in urine for 48 or 72 h following intravenous or intramuscular administration, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten horses were intravenously and/or intramuscularly administered dermorphin (9.3 ± 1.0 μg/kg), and plasma concentration vs. time data were evaluated using compartmental and noncompartmental analyses.
Report a problemFND-2537617011

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.